Clinical Trial Update: Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules [Phase 2]

View source ↗

Summary

Phase 2a dose-ranging study assessing safety and effectiveness of AA4500 for Dupuytren's Disease nodules has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dupuytren Disease

Drugs mentioned

• AA4500

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Dupuytren's Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-07-07